Biotech Equities Technical Momentum -- Research on Ironwood Pharma, Neurocrine Biosciences, Rigel Pharma, and Seattle Genetics - San Diego, California News Station - KFMB Channel 8 - cbs8.com

Biotech Equities Technical Momentum -- Research on Ironwood Pharma, Neurocrine Biosciences, Rigel Pharma, and Seattle Genetics

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Investor-Edge

Editor Note: For more information about this release, please scroll to bottom.

LONDON, May 8, 2014 /PRNewswire/ --


The trading session on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,518.54, up 0.72% and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the day 0.56% higher at 1,878.21. During the trading session eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.23% higher at 668.01, and the index has advanced 2.50% in the previous three months. Investor-Edge has initiated coverage on the following equities: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) and Seattle Genetics Inc. (NASDAQ: SGEN). Free technical research on IRWD, NBIX, RIGL and SGEN can be downloaded upon signing up at:

http://www.investor-edge.com/2287-register

Shares in Ironwood Pharmaceuticals Inc. finished Wednesday's session 2.65% lower at $12.11. A total of 2.23 million shares were traded, above its three months average volume of 1.58 million shares. The stock moved between $11.81 and $12.50 during the session. Ironwood Pharmaceuticals Inc.'s shares have gained 2.71% in the previous three trading sessions and 11.20% in the last one month. Additionally, the stock has advanced 4.31% from the beginning of 2014. The company's shares are trading below their 50-day moving average. Moreover, the stock's 50-day moving average of $12.37 is above its 200-day moving average of $11.92. Ironwood Pharmaceuticals Inc.'s stock has a Relative Strength Index (RSI) of 56.73. Sign up today to read free research on IRWD at:

http://www.investor-edge.com/2287-IRWD-08May2014.pdf

On Wednesday, shares in Neurocrine Biosciences Inc. fluctuated between $12.85 and $13.43 before ending the session 0.07% lower at $13.33. The company's stock reported a trading volume of 0.62 million shares, which was below its three months average volume of 1.00 million shares. Over the previous three trading sessions and on YTD basis, shares in Neurocrine Biosciences Inc. have gained 1.52% and 42.72%, respectively. However, the company's shares have fallen by 4.10% in the last one month. Neurocrine Biosciences Inc.'s stock is trading below its 50-day and 200-day moving averages of $15.48 and $13.48, respectively. Additionally, the company's shares have an RSI of 42.40. Sign up today to read free research on NBIX at:

http://www.investor-edge.com/2287-NBIX-08May2014.pdf

Shares in Rigel Pharmaceuticals Inc. fell by 8.94% on Wednesday, closing the day at $2.75. The stock recorded a trading volume of 1.47 million shares, which was above its three months average volume of 0.99 million shares. The stock oscillated between $2.64 and $3.14 during the session. Rigel Pharmaceuticals Inc.'s shares have lost 11.58% in the previous three trading sessions, 21.20% in the last one month and 3.51% since the start of this year. The company's shares are trading below their 50-day and 200-day moving averages of $3.71 and $3.35, respectively. Furthermore, the company's stock has an RSI of 36.47. On the same day, Rigel Pharmaceuticals Inc. announced its Q1 2014 financial results. For the Q1 2014, the company reported a net loss of $22.3 million, or $0.25 per diluted share, compared to a net loss of $25.6 million, or $0.29 per diluted share, in Q1 2013. Sign up today to read free research on RIGL at:

http://www.investor-edge.com/2287-RIGL-08May2014.pdf

On Wednesday, Seattle Genetics Inc.'s stock recorded a trading volume of 1.01 million shares, below its three months average volume of 1.22 million shares. On Wednesday, the stock finished the day at $34.21, which was 0.29% higher its previous day's closing of $34.11, and registered an intraday range of $32.61 and $34.51. However, Seattle Genetics Inc.'s stock has declined 0.84% in the previous three trading sessions and 15.43% in the last one month. Also, the company's shares have fallen by 14.24% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $45.00 and $43.31, respectively. Moreover, the company's stock and has an RSI of 31.66. Sign up today to read free research on SGEN at:

http://www.investor-edge.com/2287-SGEN-08May2014.pdf

EDITOR'S NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and Midwest Television, Inc. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.